OBI Pharma and TegMine Therapeutics Enter ADC Collaboration to Target Cancer-Specific Glycans

OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugate...

June 10, 2025 | Tuesday | News
Sanofi Begins Early Q3 Shipments of Beyfortus to Meet Growing Demand for RSV Protection in Infants

Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV)...

June 10, 2025 | Tuesday | News
SOLVE FSHD and Modalis Partner to Advance CRISPR-Based Epigenome Editing Therapy for Muscular Dystrophy

-SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Ther...

June 09, 2025 | Monday | News
Samsung Bioepis Partners with NIPRO to Advance Biosimilars in Japan

Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced that the company has entered into a license, development and commercialization agreem...

June 09, 2025 | Monday | News
Regeneron and Sanofi’s Dupixent Shows Strong Efficacy in Atopic Dermatitis Patients With Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall dise...

June 09, 2025 | Monday | News
Alvotech and Dr. Reddy’s Partner to Co-Develop Global Biosimilar for Keytruda®

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“...

June 06, 2025 | Friday | News
Agenus and Zydus Forge Strategic Partnership to Advance BOT/BAL Immunotherapy and Launch BioCDMO Operations in the U.S.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifescienc...

June 05, 2025 | Thursday | News
Acerand Therapeutics Doses First Patient in Phase I Trial of Novel CYP11A1 Inhibitor ACE-232 for Prostate Cancer

Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule therapies in oncology, toda...

June 05, 2025 | Thursday | News
Forging the Future of Biomanufacturing: How VVMF and Cytiva Are Elevating Australia’s Global Role

As the world recalibrates its life sciences infrastructure post-pandemic, Australia is stepping up as a regional powerhouse in biomanufacturing—espec...

June 05, 2025 | Thursday | Interaction
The Challenge of Modern Drug Discovery

Enter Generative AI: A Paradigm Shift Today, generative AI is changing this equation. Unlike traditional AI that analyzes existing data, generative AI can...

June 03, 2025 | Tuesday | Expert Opinion
Nxera Pharma Reaches Key Development Milestone in Diabetes Collaboration with Eli Lilly

Nxera Pharma Co., Ltd. announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly a...

June 02, 2025 | Monday | News
Astellas Inks $1.54 Billion Licensing Deal with Evopoint for ADC Candidate XNW27011 Targeting CLDN18.2

- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW2...

May 30, 2025 | Friday | News
Celltrion Secures Full Interchangeability Designation for YUFLYMA® Across All Adalimumab Dosage Forms in the U.S.

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimil...

May 27, 2025 | Tuesday | News
AnnJi’s AJ201 Shows Positive Clinical Signals in Phase 1/2a Trial for Rare Neuromuscular Disease SBMA

AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and...

May 23, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close